Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220584 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Trial of Donepezil in Fragile X Syndrome
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00220584: Completed Phase 1 study, sponsored by Stanford University.
NCT00220584 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220584, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability. Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that specific brain regions using the neurochemical, acetylcholine, show significantly reduced activation during learning. Since donepezil is a medication that enhances acetylcholine function in the brain, the purpose of this study is to determine if donepezil has any beneficial effect on behavior or cognition in subjects with fragile X syndrome.
Interventions
- DRUG donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220584
The ClinicalTrials.gov registry entry for NCT00220584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which donepezil is the first listed.
NCT00220584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00220584 about?
NCT00220584 is a clinical study titled "An Open-Label Trial of Donepezil in Fragile X Syndrome". Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability. Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that specific brain regions using the neurochemical, acetylcholine, show significantly reduced activation during learning. S...
What is the current status of trial NCT00220584?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00220584?
The interventions under investigation include: donepezil (DRUG).
Who is sponsoring clinical trial NCT00220584?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.